10x Genomics, Inc. (TXG)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in 10x Genomics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

10x Genomics, Inc. (TXG) has returned 30.17% so far this year and 143.18% over the past 12 months.

Based on dividend-adjusted daily data since Sep 12, 2019, TXG's average daily return is +0.03%, while the average monthly return is +0.32%. At this rate, your investment would double in approximately 18.1 years.

Historically, 49% of months were positive and 51% were negative. The best month was Nov 2022 with a return of +42.2%, while the worst month was Apr 2022 at -37.2%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 6 months.

On a daily basis, TXG closed higher 49% of trading days. The best single day was Nov 10, 2022 with a return of +24.4%, while the worst single day was Oct 10, 2024 at -24.7%.

10x Genomics, Inc. has an annualized alpha of -10.61%, beta of 1.40, and R² of 0.18 versus S&P 500 Index. Calculated based on daily prices since September 13, 2019.

• This stock participated in 196.90% of S&P 500 Index downside but only 145.60% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.18 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

TXG ranks 89 for risk / return — in the top 89% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for 10x Genomics, Inc. (TXG) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the 10x Genomics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the 10x Genomics, Inc. was 96.47%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current 10x Genomics, Inc. drawdown is 89.51%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of 10x Genomics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how 10x Genomics, Inc. is priced in the market compared to other companies in the Health Information Services industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.